Ariceum Therapeutics GmbH. (10/27/22). "Press Release: Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership". Berlin & North Augusta, SC.

	Organisation	Ariceum Therapeutics GmbH
	Group	Ariceum Therapeutics (Group)
	Organisation 2	AmbioPharm Inc. (APi)
	Group	Ambio Pharmaceuticals (Group)
	Product	contract manufacturing (drugs)
	Product 2	peptide synthesis
	Person	Rüdiger, Manfred (Ariceum Therapeutics 202206 CEO before Catalym + Affectis + Kiadis Pharma + LSP Munich)
	Person 2	DaFonseca, Mark (Ambio Pharmaceuticals 202210 EVP Sales + Global BusDev at AmbioPharm before CoreRx)

AmbioPharm to provide cGMP peptide synthesis and support for clinical radiopharmaceutical manufacturing

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership for the manufacture and supply of peptide conjugates to be used by Ariceum in future clinical studies.

AmbioPharm is supporting Ariceum with cGMP manufacturing and supply of peptide conjugates that will be radio-labelled as the radiopharmaceutical end-product used in upcoming clinical trials. Radio-labelled receptor-binding peptides are an important class of radiopharmaceuticals for targeted tumor diagnosis and therapy and will be used in clinical trials of Ariceum’s lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers, currently in Phase I/II. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.

As a peptide contract development and manufacturing organization (CDMO) providing cGMP peptide APIs with capabilities ranging from research to commercial scales, AmbioPharm actively engages with innovative biopharmaceutical companies in developing first-in-class, best-in-class, and breakthrough peptide technologies that utilize AmbioPharm’s peptide manufacturing expertise and in-depth scientific experience in novel and conventional peptide chemistry.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “Ariceum is very pleased to be partnering with AmbioPharm. As we build our platform and continue to advance our lead product, satoreotide, towards clinical trials, we are delighted to be supported by such a well-established and reliable manufacturer of high-quality, FDA-inspected peptide APIs.”

Michael W. Pennington, PhD, Chief Scientific Officer at AmbioPharm, added: “We are delighted to play a role in the synthesis of this peptide ‘theranostic’ that will be a valuable resource for the treatment and diagnosis of certain hard-to-treat neuroendocrine cancers.”

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: [email protected]

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: [email protected]

AmbioPharm, Inc.
Mark DaFonseca, EVP Sales & Global Business Development
Email: [email protected]

Record changed: 2024-01-06